The Health and Human Services Commission (HHSC) updated the Medicaid and Children’s Health Insurance Program (CHIP) pharmacy benefit coverage for the Spikevax COVID-19 vaccine.
On January 31, 2022, the U.S. Food and Drug Administration (FDA) issued full approval of the Moderna COVID-19 Vaccine, now marketed as Spikevax, for individuals 18 years of age and older. Spikevax has the same formulation as the emergency use authorization (EUA) Moderna COVID-19 Vaccine and the same administration schedule. The primary series of two doses are given by a healthcare provider one month apart. The original Moderna COVID-19 vaccine is also available under the EUA. Spikevax can be used interchangeably with the EUA Moderna COVID-19 Vaccine without any safety or effectiveness concerns.
Spikevax is the brand name for the Moderna COVID-19 vaccine and has its own unique National Drug Code (NDC). Beginning June 1, 2022, Medicaid will cover the brand name Spikevax COVID-19 Vaccine NDCs in the table below for Medicaid and CHIP as a payable pharmacy benefit.
|Spikevax COVID-19 Vaccine||0.5 mL||80777-0100-11|
|Spikevax COVID-19 Vaccine||0.5 mL||80777-0100-99|